BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1741 related articles for article (PubMed ID: 19707098)

  • 1. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing peripheral edema in patients with arterial hypertension.
    Epstein BJ; Roberts ME
    Am J Ther; 2009; 16(6):543-53. PubMed ID: 19636244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
    de la Sierra A
    J Hum Hypertens; 2009 Aug; 23(8):503-11. PubMed ID: 19148104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension.
    White WB
    Blood Press Monit; 2008 Apr; 13(2):123-9. PubMed ID: 18347448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective.
    Kjeldsen SE; Weber M; Oparil S; Jamerson KA
    Blood Press; 2008; 17(5-6):260-9. PubMed ID: 19061055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy.
    Oparil S; Weber M
    Postgrad Med; 2009 Mar; 121(2):25-39. PubMed ID: 19332960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension combination therapy with renin-angiotensin system blockers].
    Soucek M
    Vnitr Lek; 2009 Sep; 55(9):719-23. PubMed ID: 19785368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE
    Clin Exp Hypertens; 2010 Jan; 32(1):35-42. PubMed ID: 20144071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of antihypertensive prescription and associated blood pressure control in Japan.
    Mori H; Ukai H; Yamamoto H; Saitou S; Hirao K; Yamauchi M; Umemura S
    Hypertens Res; 2006 Mar; 29(3):143-51. PubMed ID: 16755149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in hypertension.
    Gradman AH; Basile JN; Carter BL; Bakris GL;
    J Am Soc Hypertens; 2010; 4(1):42-50. PubMed ID: 20374950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.